In older adults with type 2 diabetes, use of human regular insulin delivered by V-Go ® demonstrated similar glycemic control with no increased hypoglycemia risk compared to use of rapid acting insulin ...
BRIDGEWATER, N.J., June 25, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device—a simple, all-in-one, ...
BRIDGEWATER, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers V-Go® Wearable Insulin Delivery device, a simple, all-in-one ...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products ...
* Valeritas V-GO wearable insulin delivery device provided significant and sustained A1C reductions and achieved a1c glycemic targets in patients with type 2 diabetes Source text for Eikon: Further ...
Deal includes $10 million USD upfront payment to Zealand and sales-based milestones Certain inventory related to V-Go ® and employees also included under the terms of the deal Agreement is part of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results